Blueprint Medicines Corporation
Q1 2022 Earnings Call Transcript

Published:

  • Disclaimer*:
    This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
  • Operator:
    00
  • Jenna Cohen:
    00
  • Kate Haviland:
    02
  • Christy Rossi:
    05
  • Philina Lee:
    10
  • Becker Hewes:
    13
  • Mike Landsittel:
    18
  • Operator:
    21
  • Marc Frahm:
    21
  • Becker Hewes:
    22
  • Marc Frahm:
    23
  • Christy Rossi:
    24
  • Marc Frahm:
    25
  • Operator:
    25
  • Dane Leone:
    25
  • Kate Haviland:
    26
  • Christy Rossi:
    27
  • Kate Haviland:
    29
  • Christy Rossi:
    29
  • Becker Hewes:
    29
  • Operator:
    32
  • Elizabeth:
    32
  • Kate Haviland:
    32
  • Christy Rossi:
    32
  • Kate Haviland:
    34
  • Operator:
    35
  • Reni Benjamin:
    35
  • Kate Haviland:
    36
  • Christy Rossi:
    36
  • Philina Lee:
    38
  • Reni Benjamin:
    39
  • Operator:
    39
  • Brad Canino:
    39
  • Kate Haviland:
    39
  • Becker Hewes:
    40
  • Operator:
    Thank you. Our next question comes from the line of Michael Schmidt from Guggenheim Securities. Please, Michael, your line is now open.
  • Unidentified Analyst:
    41
  • Becker Hewes:
    42
  • Unidentified Analyst:
    43
  • Operator:
    43
  • Andrew Berens:
    43
  • Becker Hewes:
    44
  • Andrew Berens:
    46
  • Operator:
    46
  • Mike Ulz:
    46
  • Kate Haviland:
    47
  • Christy Rossi:
    47
  • Kate Haviland:
    48
  • Operator:
    49
  • David Lebowitz:
    49
  • Kate Haviland:
    50
  • Christy Rossi:
    50
  • David Lebowitz:
    51
  • Kate Haviland:
    52
  • Jenna Cohen:
    52
  • Christy Rossi:
    52
  • David Lebowitz:
    53
  • Kate Haviland:
    53
  • David Lebowitz:
    53
  • Christy Rossi:
    53
  • David Lebowitz:
    54
  • Operator:
    54
  • Eun Yang:
    54
  • Kate Haviland:
    55
  • Philina Lee:
    55
  • Kate Haviland:
    56
  • Christy Rossi:
    56
  • Kate Haviland:
    57
  • Eun Yang:
    58
  • Becker Hewes:
    58
  • Philina Lee:
    58
  • Christy Rossi:
    Sorry I missed that last part, I apologize, yes. Hematologist versus allergists, yes. So what we see is that non-advanced patients generally are managed by allergy primarily hematology is often involved in co-managing these patients and so we expect that our efforts will be primarily focused in an allergy, as well as making pathology call points that were already focused for the advanced patients.
  • Eun Yang:
    58
  • Christy Rossi:
    58
  • Philina Lee:
    58
  • Christy Rossi:
    58
  • Philina Lee:
    58
  • Kate Haviland:
    58
  • Christy Rossi:
    58
  • Eun Yang:
    59
  • Becker Hewes:
    59
  • Operator:
    60
  • Kate Haviland:
    60
  • Operator:
    61

Other Blueprint Medicines Corporation earnings call transcripts: